Abstract
The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P
| Original language | English |
|---|---|
| Pages (from-to) | 622-628 |
| Number of pages | 7 |
| Journal | Hypertension |
| Volume | 36 |
| Issue number | 4 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Baroreflex
- Blood pressure monitoring, ambulatory
- Calcium antagonists
- Diabetes mellitus
- Hypertension, essential
ASJC Scopus subject areas
- Internal Medicine
Cite this
Lacidipine and blood pressure variability in diabetic hypertensive patients. / Frattola, Alessandra; Parati, Gianfranco; Castiglioni, Paolo; Paleari, Felice; Ulian, Luisa; Rovaris, Giovanni; Mauri, Gabriele; Di Rienzo, Marco; Mancia, Giuseppe.
In: Hypertension, Vol. 36, No. 4, 2000, p. 622-628.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lacidipine and blood pressure variability in diabetic hypertensive patients
AU - Frattola, Alessandra
AU - Parati, Gianfranco
AU - Castiglioni, Paolo
AU - Paleari, Felice
AU - Ulian, Luisa
AU - Rovaris, Giovanni
AU - Mauri, Gabriele
AU - Di Rienzo, Marco
AU - Mancia, Giuseppe
PY - 2000
Y1 - 2000
N2 - The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P
AB - The aim of our study was to assess the effects of lacidipine, a long-acting calcium antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex sensitivity. In 10 mildly to moderately hypertensive patients with type II diabetes mellitus (aged 18 to 65 years), 24-hour ambulatory blood pressure was continuously monitored noninvasively (Portapres device) after a 3-week pretreatment with placebo and a subsequent 4-week once daily lacidipine (4 mg) or placebo treatment (double-blind crossover design). Systolic blood pressure, diastolic blood pressure, and heart rate means were computed each hour for 24 hours (day and night) at the end of each treatment period. Similar assessments were also made for blood pressure and heart rate variability (standard deviation and variation coefficient) and for 24-hour baroreflex sensitivity, which was quantified (1) in the time domain by the slope of the spontaneous sequences characterized by progressive increases or reductions of systolic blood pressure and RR interval and (2) in the frequency domain by the squared ratio of RR interval and systolic blood pressure spectral power ≃0.1 and 0.3 Hz over the 24 hours. Compared with placebo, lacidipine reduced the 24-hour, daytime, and nighttime systolic and diastolic blood pressure (P
KW - Baroreflex
KW - Blood pressure monitoring, ambulatory
KW - Calcium antagonists
KW - Diabetes mellitus
KW - Hypertension, essential
UR - http://www.scopus.com/inward/record.url?scp=0033779354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033779354&partnerID=8YFLogxK
M3 - Article
C2 - 11040246
AN - SCOPUS:0033779354
VL - 36
SP - 622
EP - 628
JO - Hypertension
JF - Hypertension
SN - 0194-911X
IS - 4
ER -